Saudi Pharmaceutical Industries & Medical Appliances Corp. (SPIMACO) signed today a memorandum of understanding (MoU) with Saudi Technology Development and Investment Co. (Taqnia) to invest and acquire specialized biotech drugs that are in the final stages of registration.

 

Under the renewable one-year agreement, the drugs could be newly innovated or similar to those of other international brands, which SPIMACO will partner with in order to localize production.

 

The move is in line with Saudi Arabia’s Vision 2030 economic diversification plan, which  aims to raise local pharmaceutical production to 40 percent from 20 percent by 2020.

 

The MoU enables SPIMACO to enter into research and development of biotech drugs, the firm said in a statement to Tadawul.

 

Developing and registering these drugs requires more funding compared to ordinary drugs, and it will take a long time before seeing any return on investment for these drugs, SPIMACO said.

 

The MoU is effective immediately and it has no related parties, the statement said.

 

The company will reveal any further developments as they occur, it added.

Comments 0

Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Market Indices

Created with Highstock 6.0.710:…10:0011:0012:0013:0014:0015:0012,080.0012,090.0012,100.0012,110.0012,120.00
Close : 12102.55 | Jan 2, 15:20

Quotes

Created with Highstock 6.0.710:…10:0011:0012:0013:0014:0015:0031.8031.9032.0032.1032.20
Close : 32.00 | Jan 2, 15:18


Call Request

Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.

Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website